Skip to main navigation
Go to Cumberland Pharmaceuticals, Inc. homepage
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
Contact
Contact

Financial Information

Latest Earnings Quarter

Show all

Third Quarter 2025

  • Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth

Latest 10-Q

Form Filing date View
10-Q Nov 07, 2025
View HTML
0001087294-25-000020.pdf
0001087294-25-000020.rtf
0001087294-25-000020.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Form: 10-Q
Nov 07, 2025
View HTML
0001087294-25-000020.pdf
0001087294-25-000020.rtf
0001087294-25-000020.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Latest 10-K

Form Filing date View
10-K Mar 09, 2026
View HTML
0001087294-26-000020.pdf
0001087294-26-000020.rtf
0001087294-26-000020.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Form: 10-K
Mar 09, 2026
View HTML
0001087294-26-000020.pdf
0001087294-26-000020.rtf
0001087294-26-000020.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Latest Proxy Statement

Form Filing date View
DEFA14A Mar 09, 2026
View HTML
0001087294-26-000027.pdf
0001087294-26-000027.rtf
0001087294-26-000027.xls
Form: DEFA14A
Mar 09, 2026
View HTML
0001087294-26-000027.pdf
0001087294-26-000027.rtf
0001087294-26-000027.xls

Share Related Items

Market Capitalization (Mil) $43.08
Shares Outstanding (Mil) 14.96
Shares Outstanding, Average (FY) (Mil) 14.85
Float (Mil) 8.39

Data provided by Kaleidoscope.

Source: LSEG

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy
Accessibility Statement
Terms of Use